SPOCK3抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Human left kidney tissue, Human cerebrum tissue, Mouse brain tissue, HL-60 cell lysates, Primary antibody: P09714(SPOCK3 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09714(SPOCK3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SPOCK3 antibody is a research tool designed to detect and study SPOCK3 (SPARC/osteonectin, CWCV, and Kazal-like domains proteoglycan 3), a protein encoded by the SPOCK3 gene in humans. SPOCK3 belongs to the SPOCK family, which includes extracellular matrix-associated proteoglycans involved in cell adhesion, proliferation, and migration. Structurally, SPOCK3 contains conserved domains such as thrombospondin, EGF-like, and Kazal-type serine protease inhibitor motifs, suggesting roles in extracellular matrix remodeling and cellular signaling.

While SPOCK1 and SPOCK2 are better characterized, SPOCK3 remains less studied, though it is implicated in nervous system development, tumorigenesis, and tissue repair. Antibodies against SPOCK3 enable researchers to investigate its expression patterns, localization, and interactions in various tissues. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Recent studies highlight SPOCK3's potential involvement in cancers, including glioblastoma and colorectal cancer, where it may regulate invasion and metastasis. It is also explored in neurodegenerative contexts, such as Alzheimer’s disease, due to its neural expression. The development of SPOCK3 antibodies supports ongoing efforts to elucidate its biological functions and therapeutic relevance, particularly in diseases with extracellular matrix dysregulation. Validation of these antibodies for specificity and cross-reactivity remains critical for reliable experimental outcomes.